BR0315482A - Composições farmacêuticas e formas de dosagem para liberações bucal e sublingual da tizanidina e métodos de administração da tizanidina de forma sublingual ou bucal - Google Patents

Composições farmacêuticas e formas de dosagem para liberações bucal e sublingual da tizanidina e métodos de administração da tizanidina de forma sublingual ou bucal

Info

Publication number
BR0315482A
BR0315482A BR0315482-3A BR0315482A BR0315482A BR 0315482 A BR0315482 A BR 0315482A BR 0315482 A BR0315482 A BR 0315482A BR 0315482 A BR0315482 A BR 0315482A
Authority
BR
Brazil
Prior art keywords
tizanidine
sublingual
methods
pharmaceutical compositions
oral
Prior art date
Application number
BR0315482-3A
Other languages
English (en)
Inventor
Itzhak E Lerner
Moshe Flashner-Barak
Vered Rosemberger
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR0315482A publication Critical patent/BR0315482A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS E FORMAS DE DOSAGEM PARA LIBERAçõES BUCAL E SUBLINGUAL DA TIZANIDINA E MéTODOS DE ADMINISTRAçãO DA TIZANIDINA DE FORMA SUBLINGUAL OU BUCAL". Administrações sublingual e bucal da tizanidina de supressão dos espasmos musculares aumentam a biodisponibilidade evitando o metabolismo de primeira passagem no fígado e reduzem a variação da biodisponibilidade entre pacientes.
BR0315482-3A 2002-11-12 2003-11-03 Composições farmacêuticas e formas de dosagem para liberações bucal e sublingual da tizanidina e métodos de administração da tizanidina de forma sublingual ou bucal BR0315482A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42532602P 2002-11-12 2002-11-12
PCT/US2003/035002 WO2004043431A1 (en) 2002-11-12 2003-11-03 Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally

Publications (1)

Publication Number Publication Date
BR0315482A true BR0315482A (pt) 2005-08-23

Family

ID=32312969

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315482-3A BR0315482A (pt) 2002-11-12 2003-11-03 Composições farmacêuticas e formas de dosagem para liberações bucal e sublingual da tizanidina e métodos de administração da tizanidina de forma sublingual ou bucal

Country Status (12)

Country Link
US (1) US20040122065A1 (pt)
EP (1) EP1567124A1 (pt)
JP (1) JP2006508122A (pt)
KR (1) KR100801946B1 (pt)
CN (1) CN1738600A (pt)
AU (1) AU2003287488B8 (pt)
BR (1) BR0315482A (pt)
CA (1) CA2505861A1 (pt)
EA (1) EA200500764A1 (pt)
MX (1) MXPA05005038A (pt)
NZ (1) NZ540106A (pt)
WO (1) WO2004043431A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070036797A (ko) * 2004-07-26 2007-04-03 테바 파마슈티컬 인더스트리즈 리미티드 장용 코팅된 중심정을 갖는 제형
CA2612480A1 (en) * 2005-08-01 2007-02-08 Teva Pharmaceutical Industries Ltd. Tizanidine compositions and methods of treatment using the compositions
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
CN101045051B (zh) * 2006-04-12 2010-05-26 四川科瑞德制药有限公司 替扎尼定或其衍生物在制备延长快波睡眠的药物中的用途
CN102065845A (zh) * 2008-06-11 2011-05-18 阿斯利康(瑞典)有限公司 含有(2s)-(4e)-n-甲基-5-(5-异丙氧基吡啶-3-基)-戊-4-烯-2-胺的舌下组合物
US20100291160A1 (en) * 2009-05-13 2010-11-18 Carver David R Pharmaceutical system for trans-membrane delivery
EP2442650B1 (en) * 2009-06-12 2015-08-26 Cynapsus Therapeutics Inc. Sublingual apomorphine
PL2338473T3 (pl) 2009-12-18 2017-07-31 Mdm S.P.A. Postacie farmaceutycznej dawki tizanidyny i drogi jej podawania
AU2011343429B2 (en) 2010-12-16 2016-10-20 Sunovion Pharmaceuticals Inc. Sublingual films
US20210000740A1 (en) * 2018-02-27 2021-01-07 Delpor, Inc. Compositions for small molecule therapeutic agent compounds
US20220193043A1 (en) 2019-03-29 2022-06-23 Cipla Limited Pharmaceutical Combination Formulations Comprising Tizanidine, Resveratrol and Piperine
CN113081997A (zh) * 2021-04-01 2021-07-09 杭州泓友医药科技有限公司 一种盐酸替扎尼定胶囊剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition
GB1142325A (en) * 1965-05-14 1969-02-05 Higham Stanley Russell Means for administering drugs
GB1230472A (pt) * 1967-07-10 1971-05-05
US4150113A (en) * 1969-06-03 1979-04-17 Telec S.A. Enzymatic dentifrices
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
FR2278317A1 (fr) * 1974-07-19 1976-02-13 Commissariat Energie Atomique Implant buccal pour administrer des produits solubilisables
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
GB1559811A (en) * 1975-07-28 1980-01-30 Sandoz Ltd Pharmaceutically active benzothiadiazole derivatives
US4229447A (en) * 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
NL8702523A (nl) * 1986-11-03 1988-06-01 Sandoz Ag Farmaceutische preparaten met analgetische werking en werkwijze voor het bereiden of vervaardigen en toepassen van deze preparaten.
RU2109509C1 (ru) * 1991-12-24 1998-04-27 Яманути Фармасьютикал Ко., Лтд. Композиция для буккального введения лекарственного средства и способ ее получения
WO1993015724A1 (en) 1992-02-18 1993-08-19 Nippon Shinyaku Co., Ltd. Fast soluble tablet
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
IL127955A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) * 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
BR0215413A (pt) * 2001-12-24 2004-12-14 Teva Pharma Formula dosada com um comprimido central de ingrediente ativo encapado em uma capa anular prensada de material em pó ou granulado e processo e conjunto de ferramentas para a sua produção
CN1649569B (zh) * 2002-03-04 2010-05-05 特瓦制药工业有限公司 控释剂型

Also Published As

Publication number Publication date
EP1567124A1 (en) 2005-08-31
CA2505861A1 (en) 2004-05-27
JP2006508122A (ja) 2006-03-09
EA200500764A1 (ru) 2005-12-29
AU2003287488A1 (en) 2004-06-03
NZ540106A (en) 2008-03-28
KR20050075398A (ko) 2005-07-20
WO2004043431A1 (en) 2004-05-27
US20040122065A1 (en) 2004-06-24
AU2003287488B8 (en) 2007-05-17
AU2003287488B2 (en) 2007-04-05
MXPA05005038A (es) 2005-07-01
CN1738600A (zh) 2006-02-22
KR100801946B1 (ko) 2008-02-12

Similar Documents

Publication Publication Date Title
BRPI0418228B8 (pt) forma de dosagem, e, método de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
DK1115384T3 (da) Fentanyl-præparat til behandling af akutte smerter
WO2005065317A3 (en) Effervescent oral fentanyl dosage form
HUP0401714A2 (hu) Propiverin vagy gyógyászatilag elfogadható sóinak nyújtott hatóanyag-eladású, orális adagolási formái
HUP0401191A2 (hu) Opioid agonistát, valamint leadható és álcázott antagonistát tartalmazó készítmények
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
DK1587514T3 (da) Hurtigvirkende farmaceutisk præparat
CO5611096A2 (es) Forma de dosificacion farmaceutica para administracion mucosal
HK1100166A1 (en) Effervescent oral opiate dosage form
HUP0302319A2 (hu) Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
IS6892A (is) Lyfjasamsetningar, skammtaform og aðferðir til aðgefa epóþílon um munn
BR0315482A (pt) Composições farmacêuticas e formas de dosagem para liberações bucal e sublingual da tizanidina e métodos de administração da tizanidina de forma sublingual ou bucal
HUP0402178A2 (hu) 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény
TW200611697A (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
AU2003294520A1 (en) Temporary, pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing
HUP0402326A2 (hu) Gyógyszerkészítmény addikció megelőzésére fájdalom kezelésében
MY141008A (en) Oral formulations of deoxypeganine and their uses
ATE210448T1 (de) Arzneizubereitung zur verabreichung von thiocolchicosid durch die mundschleimhaut
WO2005062722A3 (en) Fexofenadine containing pharmaceutical formulation
AU2003235931A1 (en) Vintoperol-containing medicinal composition for transdermal administration
HUP0301337A2 (hu) Terbinafint tartalmazó orális gyógyszerkészítmények és alkalmazásuk
TW200611686A (en) Effervescent oral opiate dosage forms and methods of administering opiates
TW200611696A (en) Effervescent oral fentanyl dosage form and methods of administering fentanyl
WO2005051489A3 (en) Fast dissolving solid oral dosage forms of galanthamine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.